# Korro Bio

OPERA（Oligonucleotide Promoted Editing of RNA）平台支撑 KRRO-110（处于 REWRITE I/IIa 期研究，2025 年 3 月获 FDA 孤儿药资格）与新选定的开发候选 KRRO-111，后者在 PiZZ 小鼠模型中实现超过 90% 的 SERPINA1 转录本编辑与约 90% 的修复功能型 AAT 蛋白；公司截至 2026 年 3 月 31 日持有现金与有价证券 1.571 亿美元，资金跑道延续至 2028 年下半年。

Source: https://cn.bioecon.ru/companies/korro-bio/
Updated: 2026-08-15

- 国家: United States
- 代码: NASDAQ:KRRO

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2026年3月9日宣布的私募配售(PIPE)融资$8500万 | https://www.nasdaq.com/press-release/korro-announces-oversubscribed-85-million-private-placement-2026-03-09 |
| 监管批准 | KRRO-110获FDA(2025年3月)及EMA(2025年7月)授予孤儿药资格 | https://ir.korrobio.com/news-releases/news-release-details/korro-receives-european-medicines-agency-orphan-drug-designation/, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-second-quarter-2025-financial-results-and-provides, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/, https://synapse.patsnap.com/drug/a4ccb7d44d6e3790cc6377025558de92, https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-ex99_1.htm |
| 监管批准 | KRRO-110 获得 FDA 快速通道认定 | https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| 监管批准 | RNA编辑技术获FDA研究性新药(IND)许可 | https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| 营收 | 截至2025年9月30日止九个月的合作收入为$510万 | https://ir.korrobio.com/investor-relations/, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-second-quarter-2025-financial-results-and-provides, https://ir.korrobio.com/news-releases/news-release-details/korro-reports-third-quarter-financial-results-provides-updates/ |
| 生产基地 | 总部位于马萨诸塞州剑桥市 60 First Street，办公及实验室面积达50,453平方英尺 | https://archinect.com/firms/release/150120950/tria-designs-innovative-headquarters-for-korro-bio/150456445, https://ir.korrobio.com/static-files/2bd4f199-86d0-4a12-b9a7-9ad29d4bf3e1 |

独立来源: archinect.com, nasdaq.com, sec.gov, synapse.patsnap.com

## 技术

- [RNA 编辑（ADAR）疗法](https://cn.bioecon.ru/technology/rna-editing-adar-therapeutics/)